Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, India.
Curr Pharm Biotechnol. 2022;23(7):920-931. doi: 10.2174/1389201022666210810094739.
Protein Tyrosine Phosphatase (PTP) superfamily is a key enzyme involved in the regulation of growth-related cell signaling cascades, such as the RAS/MAPK pathway, that directly affect cancer cell growth and metastasis. Several studies have indicated that the drug resistance observed in several late-stage tumors might also be affected by the levels of PTP in the cell. Hence, these phosphatases have been in the limelight for the past few decades as potential drug targets and several promising drug candidates have been developed, even though none of these drugs have reached the market yet. In this review, we explore the potential of PTP as a viable anti-cancer drug target by studying PTPs, their regulation of several key cancer cell signaling pathways, and how their levels affect various types of cancer. Furthermore, we present the current scenario of PTP as a molecular target and the various challenges faced in the development of PTP-targeting anti-cancer drugs.
蛋白酪氨酸磷酸酶（PTP）超家族是参与调节与生长相关的细胞信号级联反应的关键酶，如 RAS/MAPK 途径，这些反应直接影响癌细胞的生长和转移。有几项研究表明，在几个晚期肿瘤中观察到的耐药性也可能受到细胞中 PTP 水平的影响。因此，在过去几十年中，这些磷酸酶一直是潜在的药物靶点的焦点，已经开发出了几种有前途的候选药物，尽管这些药物都尚未上市。在这篇综述中，我们通过研究 PTP、它们对几种关键癌细胞信号通路的调节以及它们的水平如何影响各种类型的癌症，探讨了 PTP 作为一种可行的抗癌药物靶点的潜力。此外，我们还介绍了 PTP 作为分子靶点的现状以及在开发针对 PTP 的抗癌药物时面临的各种挑战。
